Mineralys’ Hypertension Drug Drops Blood Pressure in Phase II/III, Setting Up Market Clash

Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in a pair of clinical trials.

Scroll to Top